{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:56:09Z","timestamp":1793213769994,"version":"4.5.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background and objectives:<\/jats:title>\n            <jats:p>The incidence of morbidity and mortality in patients with type 2 diabetes mellitus is substantially correlated with cardiovascular disease and chronic kidney disease. The current guidelines recommend the use of renin-angiotensin system blockers, but recent studies probed into the effects of finerenone to mitigate the risk of cardiorenal events. This meta-analysis was performed to demonstrate the effects of finerenone on cardiorenal events, comprising cardiovascular mortality, heart failure, change in estimated glomerular filtration rate, and serum potassium levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>After screening with our eligibility criteria, 350 articles were identified with an initial literature search on multiple databases, including PubMed, Science Direct, and Cochrane Central. Seven randomized controlled trials with a total of 15\u00a0462 patients (<jats:italic toggle=\"yes\">n<\/jats:italic>=8487 in the finerenone group; <jats:italic toggle=\"yes\">n<\/jats:italic>=6975 in the control group) were included.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Patients receiving finerenone were at a reduced risk for cardiovascular mortality [HR: 0.84 (0.74, 0.95)], heart failure [OR: 0.79 (0.68, 0.92)], decrease in estimated glomerular filtration rate by 40% [OR: 0.82 (0.74, 0.91)] and by 57% [OR: 0.70 (0.59, 0.82)]; and a higher incidence of moderate hyperkalemia [OR: 2.25 (1.78, 2.84)].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Finerenone, owing to its better mineralocorticoid affinity, and a much lower risk of adverse effects, promises to be a much better alternative than other renin-angiotensin system blockers available for the treatment of chronic kidney disease patients with type 2 diabetes. Further trials should be conducted to provide more definitive evidence to assess the safety and efficacy of finerenone compared to spironolactone and eplerenone.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ms9.0000000000001180","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T12:05:35Z","timestamp":1693310735000},"page":"4973-4980","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"85","author":[{"given":"Farah","family":"Yasmin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Aamir","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Lehigh Valley Health Network, Allentown, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala","family":"Najeeb","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Raafe","family":"Atif","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Hannan","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nadeem","family":"Ahsan","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis Unit, Dow University of Health Sciences-Ojha Campus, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Moeed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Hasan","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow Medical College, Dow University of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya Muhammad","family":"Tahir","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jinnah Sindh Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Sohaib","family":"Asghar","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic - Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10]]},"reference":[{"key":"R1-20250806","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/jdi.13355","article-title":"Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: estimates from Global Burden of Disease 2017","volume":"12","author":"Li","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"suppl 1","key":"R3-20250806","first-page":"S135","article-title":"Standards of medical care in diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"R4-20250806","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00125-019-05039-w","article-title":"2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"63","author":"Buse","year":"2020","journal-title":"Diabetologia"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"R7-20250806","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertens (Dallas, Tex 1979)"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"R9-20250806","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"R11-20250806","first-page":"7428439","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis","volume":"10","author":"Fu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced ckd and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2021","journal-title":"Kidney Int Reports"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes, Obes Metab"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R18-20250806","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"R20-20250806","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"key":"R22-20250806","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"R23-20250806","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R24-20250806","doi-asserted-by":"crossref","first-page":"9995","DOI":"10.3390\/ijms22189995","article-title":"Mineralocorticoid receptor antagonists\u2014use in chronic kidney disease","volume":"22","author":"Baran","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R25-20250806","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.3389\/fphar.2021.754239","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease","volume":"12","author":"Kawanami","year":"2021","journal-title":"Front Pharmacol"},{"key":"R26-20250806","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1348-4","article-title":"Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study","volume":"20","author":"Blankenburg","year":"2019","journal-title":"BMC Nephrol"},{"key":"R27-20250806","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"R28-20250806","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"R29-20250806","first-page":"96","article-title":"Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"R30-20250806","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-Analysis of the efficacy and safety of finerenone in diabetic kidney disease","volume":"47","author":"Zheng","year":"2022","journal-title":"Kidney Blood Press Res"},{"key":"R31-20250806","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9040947","article-title":"GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists","volume":"9","author":"G\u00f3rriz","year":"2020","journal-title":"J Clin Med"},{"key":"R33-20250806","doi-asserted-by":"crossref","first-page":"e221169","DOI":"10.1001\/jamanetworkopen.2022.1169","article-title":"Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease","volume":"5","author":"Chen","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R34-20250806","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"R35-20250806","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from hans selye to the present","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol"},{"key":"R36-20250806","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S2213-8587(18)30241-9","article-title":"GLP-1 receptor agonists, CKD, and eGFR trajectory","volume":"6","author":"van Baar","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R37-20250806","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ddr.21760","article-title":"Role of mineralocorticoid receptor antagonists in kidney diseases","volume":"82","author":"Patel","year":"2021","journal-title":"Drug Dev Res"},{"key":"R38-20250806","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"R39-20250806","doi-asserted-by":"crossref","first-page":"e0254","DOI":"10.1097\/MD.0000000000010254","article-title":"The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis","volume":"97","author":"Pei","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R40-20250806","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10741-019-09790-5","article-title":"Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials","volume":"24","author":"Yang","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R41-20250806","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/02763869.2019.1588072","article-title":"An international register of systematic review protocols","volume":"38","author":"Julie","year":"2019","journal-title":"Med Ref Serv Q"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:20:00Z","timestamp":1754486400000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000001180","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"assertion":[{"value":"2023-04-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}